[ad_1]
“I spoke with the director of the Cantacuzino Institute, Coronel Oancea, in the last period of time he focused a lot on what it means to increase the testing capacity. He is also working on an immunomodulatory drug, which will soon be on the market, and has taken steps to get the old trivalent vaccine production line back on track and start testing, so that, as proposed at the institute, as of next year to be able to produce the vaccine. The immunomodulatory drug will be launched at the end of the year, “said Nicolae Ciucă.
Specialists from the National Institute for Medical-Military Research-Development “Cantacuzino” have developed a new immunomodulating product, which has properties to stimulate immunity, increasing the body’s resistance to infections, points out Agerpres.
The biggest battle, however, is over the life-saving vaccine. Recently,
When the vaccine will be available
The FDA is awaiting safety data on the new vaccine.
The United States Food and Drug Administration (FDA) has stated that it wishes to receive extended safety data for at least two months before authorizing the emergency use of any experimental vaccine created against the novel coronavirus.
Pfizer Group CEO Albert Bourla said in a message posted on the US company’s website that the submission of the authorization dossier depends on several factors, including vaccine efficacy data, which may or may not be obtained. towards the end of October.
Given the number of volunteers enrolled in its clinical trials and the dosing rate, Pfizer experts expect to get safety data on the vaccine in the third week of November. Albert Bourla said.
The filing of the dossier requesting emergency clearance by the FDA could take place “shortly” after obtaining these data, said the CEO of the Pfizer group.
He also said that data on the effectiveness of the vaccine could sooner or later be obtained if the phase III study of this vaccine recruited a sufficient number of COVID-19 patients to compare the effectiveness of the treatment. with that in the placebo group. Previously, the Pfizer group said it expects to obtain the data provided by its phase III study in October, Agerpres reports.
